kdm5a

KDM5A-IN-1 是一种可口服且具有高效性和选择性的泛组氨酸赖氨酸脱甲基酶 5 KDM5 抑制剂，抑制 KDM5A，KDM5B，KDM5C，IC50 值分别为 45 nM，56 nM 和 55 nM。KDM5A-IN-1 抑制 PC9 H3K4Me3，可用于研究癌症。

YUKA1 is a potent and cell-permeable Lysine demethylase 5A inhibitor (IC50: 2.66 μM) and less active on KDM5C (IC50, 7.12 μM). YUKA1 is inactive on KDM5B, KDM6A, or KDM6B.

CPI-455 是一种特异性的泛KDM5抑制剂，对 KDM5A 的IC50为 10 nM。它介导 KDM5 抑制，提高 H3K4me3 的整体水平，有抗肿瘤作用。

KDOAM-25 trihydrochloride increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells. KDOAM-25 trihydrochloride is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor

CPI-455 is a specific KDM5 inhibitor with IC50 value of 10 ± 1 nM for full-length KDM5A in enzymatic assays, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with target

KDOAM-25 citrate 是有效且具有高选择性的组蛋白赖氨酸脱甲基酶 5 (KDM5) 抑制剂，对 KDM5A，KDM5B，KDM5C，KDM5D 的IC50分别为 71 nM，19 nM，69 nM，69 nM。用KDOAM-25 citrate 处理的多发性骨髓瘤 MM1S 细胞显示转录起始位点的整体 H3K4 甲基化增加，增殖受损。

Ryuvidine 是一种 KDM5A 和 SETD8 双重抑制剂，是一种 DNA 损伤反应的诱导剂，具有潜在的抗癌活性，抑制 H4K20 甲基化，抑制 CDK4，可用于研究乳腺癌和红斑病。

KDOAM-25, a potent and highly selective inhibitor of histone lysine demethylases 5 (KDM5) with IC50 values of 71 nM for KDM5A, 19 nM for KDM5B, 69 nM for KDM5C, and 69 nM for KDM5D, enhances global H3K4 methylation at transcriptional start sites and reduces proliferation in multiple myeloma MM1S cells.

Roxadustat-d5 is intended for use as an internal standard for the quantification of roxadustat by GC- or LC-MS. Roxadustat is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH; IC50s = 1.4, 1.26, and 1.32 µM for HIF-PH1, HIF-PH2, and HIF-PH3, respectively). It is selective for HIF-PH over other 2-oxoglutarate-dependent dioxygenases, including lysine-specific demethylase 5A (KDM5A), KDM5B, -5C, -5D, and -6B (IC50s = >100 µM for all). Roxadustat (10-200 µM) stabilizes HIF-1α and HIF-2α in Hep3B hepatocellular carcinoma cells. It increases levels of secreted erythropoietin in Hep3B cells in a concentration-dependent manner and increases erythropoiesis in rats when administered at doses of 25 and 50 mg kg. Roxadustat reverses anemia in a rat model of chronic inflammation induced by peptidoglycan-polysaccharide, as well as a rat model of chronic kidney disease induced by 5 6 nephrectomy. It reduces tumor growth and increases survival in a murine Lewis lung carcin......

KDOAM-25 trihydrochloride 是一种有效的、高度选择性的组蛋白赖氨酸脱甲基酶 5 (KDM5) 抑制剂，能够作用于 KDM5A (IC50: 71 nM)、KDM5B (IC50: 19 nM)、KDM5C (IC50: 69 nM)、KDM5D (IC50: 69 nM)。KDOAM-25 trihydrochloride 能够提高转录起始位点的整体 H3K4 甲基化，可阻碍多发性骨髓瘤 MM1S 细胞的增殖。

KDM5-C49 (KDOAM-20) hydrochloride 是一种有效和选择性的KDM5去甲基化酶抑制剂，抑制KDM5A，KDM5B 和KDM5C 的IC50值分别为 40 nM，160 nM 和 100 nM。KDM5-C49 hydrochloride 可用于癌症的研究。

KDM5-C49 HCl (KDOAM-20 hydrochloride)KDM5-C49 HCl 是一种有效的和具有选择性的 去甲基化酶 KDM5抑制剂。KDM5-C49 HCl 是治疗癌症的候选化合物。